We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients
Read MoreHide Full Article
Gilead Sciences, Inc. (GILD - Free Report) recently announced the FDA has approved a supplemental new drug application (sNDA) for flagship HIV therapy Biktarvy.
The regulatory body approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.
The approval of Biktarvy for children weighing at least 14 kg is based on data from Cohort 3 of phase II/III open-label, single-arm study. Data from the study showed that Biktarvy low-dose tablets were effective and generally well-tolerated through 24 weeks in virologically suppressed children living with HIV-1. Cohort 3 enrolled 22 participants weighing ≥14 to <25 kg who continued on treatment for 48 weeks and could then continue to receive study drug through an extension phase.
Pediatric HIV remains a crucial health problem despite effective available treatment options for pregnant women living with HIV lowering the likelihood of perinatal HIV infection transmission.
The FDA approved Biktarvy as a once-daily single-tablet regimen for the treatment of HIV-1 infection in adults in 2018. Thereafter, in June 2019, the FDA approved labeling revisions to Biktarvy, expanding the patient population to include pediatric patients weighing at least 25 kg.
Label expansion of the treatment will boost sales of the same, which came in at $3.8 billion in the first half of 2021.
Gilead’s stock has gained 16.7% this year against the industry's decline of 10.5%.
Image Source: Zacks Investment Research
Gilead is looking to strengthen its HIV franchise, which was adversely impacted by the ongoing pandemic and the loss of exclusivity of Truvada and Atripla. Competition is stiff as well from the likes of GlaxoSmithKline (GSK - Free Report) . Gilead has collaborated with a subsidiary of Merck (MRK - Free Report) to develop and commercialize long-acting, investigational treatment combinations of Gilead’s lenacapavir and Merck’s islatravir in HIV.
The massive decline in its HCV business has forced Gilead to focus on its HIV franchise and diversify into the oncology space, which promises potential despite stiff competition.
Regeneron’s earnings estimates have been revised upward by 3.3% for 2021 and 0.3% for 2022 over the past 30 days. The stock has jumped 13.6% year to date.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients
Gilead Sciences, Inc. (GILD - Free Report) recently announced the FDA has approved a supplemental new drug application (sNDA) for flagship HIV therapy Biktarvy.
The regulatory body approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.
The approval of Biktarvy for children weighing at least 14 kg is based on data from Cohort 3 of phase II/III open-label, single-arm study. Data from the study showed that Biktarvy low-dose tablets were effective and generally well-tolerated through 24 weeks in virologically suppressed children living with HIV-1. Cohort 3 enrolled 22 participants weighing ≥14 to <25 kg who continued on treatment for 48 weeks and could then continue to receive study drug through an extension phase.
Pediatric HIV remains a crucial health problem despite effective available treatment options for pregnant women living with HIV lowering the likelihood of perinatal HIV infection transmission.
The FDA approved Biktarvy as a once-daily single-tablet regimen for the treatment of HIV-1 infection in adults in 2018. Thereafter, in June 2019, the FDA approved labeling revisions to Biktarvy, expanding the patient population to include pediatric patients weighing at least 25 kg.
Label expansion of the treatment will boost sales of the same, which came in at $3.8 billion in the first half of 2021.
Gilead’s stock has gained 16.7% this year against the industry's decline of 10.5%.
Gilead is looking to strengthen its HIV franchise, which was adversely impacted by the ongoing pandemic and the loss of exclusivity of Truvada and Atripla. Competition is stiff as well from the likes of GlaxoSmithKline (GSK - Free Report) . Gilead has collaborated with a subsidiary of Merck (MRK - Free Report) to develop and commercialize long-acting, investigational treatment combinations of Gilead’s lenacapavir and Merck’s islatravir in HIV.
The massive decline in its HCV business has forced Gilead to focus on its HIV franchise and diversify into the oncology space, which promises potential despite stiff competition.
Gilead currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Regeneron Pharmaceuticals (REGN - Free Report) which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings estimates have been revised upward by 3.3% for 2021 and 0.3% for 2022 over the past 30 days. The stock has jumped 13.6% year to date.